Research & Education

Three Optima for ALK Positive Lung Cancer

September 21, 2017 at 6:00PM HKT - Recording Available



Program Chair
Professor Tony Mok, MD, FRCP(C), FRCP (Edin), FHKCP, FHKAM(Medicine), FASCO
Chairman, Department of Clinical Oncology
The Chinese University of Hong Kong 

Prof. Solange Peters MD, PhD
Médecin Chef
Head Medical Oncology
Chair Thoracic Malignancies
Oncology Department

Centre Hospitalier Universitaire Vaudois (CHUV)

Daniel SW Tan, MD, PhD, MBBS, MRCP, Bsc
Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore
Director, Experimental Cancer Therapeutics
Unit (Phase I Unit), NCCS
Senior Clinician-Scientist,
Genome Institute of Singapore
Associate Professor (Adj),
Duke-NUS Medical School


Name of Reviewer(s): 


 Laurie Gaspar, MD Advisory Board/Honoraria from Astrazeneca.

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 


Three Optima for ALK Positive Lung Cancer

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”


Program Chair: 

Tony Mok, MD

AstraZeneca (Speaker, Ad Board, Honoraria), Roche/Genentech (Speaker, Ad Board, Honoraria), Pfizer (Speaker, Ad Board, Honoraria), Eli Lilly (Speaker, Ad Board, Honoraria), BI (Speaker, Ad Board, Honoraria), MSD (Speaker, Ad Board, Honoraria), Novartis (Speaker, Ad Board, Honoraria), BMS (Speaker, Ad Board, Honoraria), SFJ (Ad Board, Honoraria), Merck Serono (Ad Board, Honoraria), ACEA biosciences (Ad Board, Honoraria), Vertex (Ad Board, Honoraria), OncoGenex (Ad Board, Honoraria), Celgene (Ad Board, Honoraria), Ignyta (Ad Board, Honoraria), Taiho (Ad Board, Honoraria), Sanomics Ltd (Stock), Cirina (Ad Board, Stock)


Solange Peters, MD, PhD - Nothing to dislose. 

Daniel SW Tan, MD, PhD - Advisory Board and Honoraria for  Novartis.


Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:


This program will provide an updated view of the optimal management of ALK Positive Lung Cancer.

Professor Tony Mok, MD, will discuss the detection of ALK as the first step to treatment.  The use of FISH and IHC is the current standard, and beyond, the role of NGS is under intensive investigation. The identification of different types of variants and the diverse mechanisms of resistance will be addressed in terms of implications for future management.

Prof. Solange Peters will cover the treatment landscape and management strategies for frontline therapy, after disease progression and beyond in advanced ALK-positive NSCLC.  ALK disease biology and resistance mechanisms to targeted therapies will be reviewed.  Based on the current state of knowledge, the best use of the various ALK inhibitors currently available and in development will be discussed.

Dr. Dan Tan will cover the clinical challenge the management of brain metastases in the unique molecular subset of lung cancer.  The differential profiles of currently available and emerging ALK inhibitors will be discussed as well as how they might be sequenced with other therapeutic modalities to achieve durable clinical activity.

Course Objectives- After participating in this webinar learners will be able to:

  • Recognize the use of FISH and IHC to detect ALK; 
  • Demonstrate the different type of ALK  variants and mechanisms of resistance to ALK inhibitors;
  • Describe management strategies for front-line treatment and after disease progression;
  • Identify the differences in properties and CNS efficacy for ALK inhibitor;
  • Discuss the evolving paradigm for management of brain metastasis in ALK positive disease.

This sixty minute program will be an interactive event.  There will be ample opportunity for attendees to submit questions and comments to the faculty via Internet chat.

In order to receive CME credit, attendees must fill out a program evaluation.


 Financial Commercial and Conflicts of Interest Disclosure Form

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)



Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.

Financial/Commercial Relationships DISCLOSURES

A conflict of interest (COI) is created and exists when individuals in a position to control the content of CME (or their spouses/partners) have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities for which remuneration is received or expected. 

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME Department assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest were identified, reviewed and resolved fromall individuals involved in the development or able to influence and control the content of this CME activity. The IASLC CME Department assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from all IASLC CME activity presentations.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee and an independent reviewer. COI will be evaluated by the IASLC Board of Directors for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. The IASLC CME Department is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. It is also intended that any potential conflict be identified openly so that the listeners have a full disclosure of the facts and may form their own judgments about the presentation. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

All other faculty/contributors have reported no commercial affiliation associated with this conference or intent to reference off-label/unapproved uses of products or devices in their presentations.


IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

Attendees can now view IASLC Live webinars via their mobile device.  

Downloading of the Cisco WebEx Meetings app is required.

Once the app is installed on your device you will need to enter the event number for each session.

 Registration is required for all IASLC webinars.